Skip to main content
VALN
NASDAQ Life Sciences

Valneva Secures €84M in Private Placement with Warrants to Fund Vaccine Pipeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.38
Mkt Cap
$467.72M
52W Low
$5.15
52W High
$12.25
52W Position info
4.5% above low
Off High info
56% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

VALN is trading near its 52-week low of $5.15 (4.5% above the low).

Summary

Valneva SE announced the successful completion of an €84 million private placement of shares and warrants, securing vital capital for its vaccine pipeline and operations, despite significant dilution for existing shareholders.


Key Events · Financing and Capital Events · VALN

  • Significant Capital Raise

    Valneva SE secured €37 million in an initial private placement of 15,893,817 new ordinary shares, each with an attached warrant. An additional €47 million could be raised if all warrants are exercised, bringing the total potential capital to €84 million.

  • Institutional Investor Participation

    The offering was led by existing investor Frazier Life Sciences and included participation from new and existing prominent life sciences investors such as TCGX, Deep Track Capital, Cormorant Asset Management, Perceptive Advisors, Vivo Capital, Samsara BioCapital, and Nantahala Capital.

  • Dilution and Pricing Details

    The new shares represent an initial dilution of approximately 9.1% of the company's share capital. If all warrants are exercised, an additional 8.4% dilution would occur. The ABSA (share + warrant) issue price was €2.33, reflecting an effective 14.4% discount to the 3-day VWAP, while the warrant exercise price is set at a 25% premium (€2.96) to the 3-day VWAP of €2.37.

  • Use of Proceeds

    Net proceeds will be used to advance Valneva's vaccine pipeline, maximize growth of its cash-generating commercial business, and for general working capital purposes.


Analysis · VALN · Life Sciences

Valneva SE has successfully completed a significant private placement, raising €37 million upfront and potentially an additional €47 million upon full exercise of attached warrants, totaling €84 million. This capital infusion is crucial for the company, especially as it trades near its 52-week low, providing essential funding to advance its vaccine pipeline and support general corporate purposes. While the offering introduces substantial dilution for existing shareholders (9.1% initially, with an additional 8.4% if all warrants are exercised), the participation of prominent life sciences investors like Frazier Life Sciences, TCGX, Deep Track Capital, Cormorant Asset Management, Perceptive Advisors, Vivo Capital, and Samsara BioCapital signals strong institutional confidence in Valneva's long-term prospects. The warrants, exercisable at a 25% premium to the recent volume-weighted average price, further underscore this confidence. Investors should monitor the company's progress in its vaccine pipeline development and commercial business growth, as this financing provides a critical runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VALN was trading at $5.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $467.7M. The 52-week trading range was $5.15 to $12.25. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VALN - Latest Insights

VALN
Nov 13, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.84
Real-time Price: $5.90 info
Change: +$0.060 (+1%) info
Market Cap: $538.434M info
VALN
Nov 09, 2026, 10:37 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $5.79
Real-time Price: $5.90 info
Change: +$0.110 (+2%) info
Market Cap: $538.434M info
VALN
Oct 07, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.90 info
Change: +$0.290 (+5%) info
Market Cap: $538.434M info
VALN
Aug 14, 2026, 11:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.01
Real-time Price: $5.90 info
Change: -$1.11 (-16%) info
Market Cap: $538.434M info
VALN
Aug 13, 2026, 10:27 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.45
Real-time Price: $5.90 info
Change: +$0.450 (+8%) info
Market Cap: $538.434M info